Markets open

Jazz Pharmaceuticals plc

JAZZ · NASDAQ-GS

$207.73+$2.030.99%

As of: Oct 27, 12:20 PM

$206.10-$1.630.78%

· Vol 1.82K

: $205.70
: $13.48B
Open: —
: —
: $0.00 - $0.00
: $128.80 - $266.38
: —
: —
: 1.43K

About Jazz Pharmaceuticals plc

Jazz Pharmaceuticals is a specialty pharmaceutical company that makes money by developing and selling prescription medicines. Its portfolio is associated with sleep medicine, neuroscience, and oncology and hematology, serving patients through healthcare providers, pharmacies, and insurance or government payers. The supplied evidence does not identify individual products, report segment revenue contributions, or quantify the customer mix, so the relative importance of those therapeutic areas cannot be established. Jazz generated $4.3 billion of revenue in FY2025, compared with $4.1 billion in FY2024, but reported a FY2025 net loss of $0.4 billion versus FY2024 net income of $0.6 billion.

Notable Price Movement

Weekly movement commentary will appear here once it has been generated for this company.

Stories & Analysis

Jazz Pharmaceuticals plc Estimates $755 Million Q3 Financial Impact from Actio Biosciences Acquisition

Fintel · 16h ago Analysts Estimate Jazz Pharmaceuticals (JAZZ) to Report a Decline in Earnings: What to Look Out for

Zacks · 1d ago Jazz Pharmaceuticals Reports Positive Phase 3 Results For Ziihera Combination

RTTNews · 4d ago Stocks Finish Mostly Higher on Earnings Optimism

Barchart · 6d ago Will Auvelity Continue to Aid Axsome's Top-Line Growth in Q3?

Zacks · 6d ago Stocks Pressured by Tech Stock Weakness and Higher Crude Oil Prices

Barchart · Oct 20 Stocks Rebound on Strong Earnings and Lower Bond Yields

Barchart · Oct 20 Why Everyone Is Watching Jazz Pharmaceuticals (JAZZ) Right Now

Simply Wall Street · Oct 18

Symbol: JAZZ
Type: Stock
Sector: Health Care
Industry: Biotechnology: Pharmaceutical Preparations
Country: Europe
Exchange: NASDAQ-GS

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharma company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with rare disease - often with limited or no therapeutic options. We have a diverse portfolio of medicines, including leading therapies addressing epilepsies, cancers and sleep disorders. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics. Jazz is headquartered in Dublin, Ireland with research and development laboratories, manufacturing facilities and employees in multiple countries committed to serving patients worldwide.

Key Issues

Bullish view

Revenue increased from $4.1 billion in FY2024 to $4.3 billion in FY2025, showing continued top-line growth that could support a return to profitability if expenses stabilize.

Bearish view

Despite the higher revenue base, Jazz reported a $0.4 billion net loss in FY2025 after earning $0.6 billion in FY2024, indicating that growth alone has not yet translated into earnings.

Analyst Consensus

See all

Buy

19 analysts

$208

Current

—

Low

$300

Average

—

High

Average target implies +44.42% versus the current price.

Earnings History

BeatMissNo estimate

Peers

—

879.45K